Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	4/27/2007 6:55:38 AM
	Read Replies (1) of 824

EMEA concludes first accelerated assessment for a medicine for human use The European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorisation for the first medicinal product for human use that was evaluated by accelerated assessment. Accelerated assessment was introduced by the revised EU pharmaceutical legislation in November 2005. The aim of this new regulatory tool is to help speed up access of patients to new medicines of major public-health interest. Companies can request accelerated assessment provided they are able to demonstrate that their product responds to unmet medical needs or constitutes a significant improvement over the available methods of prevention, diagnosis or treatment of a condition. In 2006, the CHMP received 13 requests for accelerated assessment, 4 of which were accepted. The medicinal product, Soliris (eculizumab), from Alexion Europe SAS, besides being the first is medicinal product for which an accelerated assessment procedure was concluded successfully, also the first product submitted by a company benefiting from specific incentives for small and medium-sized enterprises (SMEs) to receive a positive opinion. Soliris, a designated orphan medicinal product, is intended to reduce haemolysis (destruction of red blood cells) in patients with paroxysmal nocturnal haemoglobinuria (PNH), a rare blood disorder in which the red blood cells are weak and are thus destroyed more rapidly than normal, causing the urine to turn red or dark during an episode (or paroxysm) of haemolysis. The EMEA review time was 147 days, within the limit of 150 days set by EU legislation for accelerated assessment. The opinion for Soliris will now be forwarded to the European Commission for adoption of a marketing authorisation decision.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next